Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong · Delayed Price · Currency is HKD 2.200
-0.005 (-0.23%)
Oct 9, 2026, 9:42 AM HKT
Wuhan YZY Biopharma Revenue
Wuhan YZY Biopharma had revenue of 35.77M CNY in the half year ending June 30, 2026, with 1,161.42% growth. This brings the company's revenue in the last twelve months to 58.26M, down -60.99% year-over-year. In the year 2025, Wuhan YZY Biopharma had annual revenue of 66.86M, down -37.99%. That makes Wuhan YZY Biopharma the 38,000th largest company in the world by revenue and 2,325th in Hong Kong.
Revenue (ttm)
58.26M CNY
Revenue Growth
-60.99%
P/S Ratio
7.20
Revenue / Employee
856.81K CNY
Employees
68
Market Cap
484.62M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.86M | -40.95M | -37.99% |
| Dec 31, 2024 | 107.81M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.28M | -9.89M | -81.28% |
| Dec 31, 2021 | 12.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| Kintor Pharmaceutical | 90.90M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |
| B&K Corporation | 602.64K |